Pennington Biomedical Research Center

TOS Past Presidents Comment on SELECT Study Results

Retrieved on: 
Tuesday, November 14, 2023

ROCKVILLE, Md., Nov. 14, 2023 /PRNewswire/ -- New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past presidents of The Obesity Society (TOS) and published in The New England Journal of Medicine.

Key Points: 
  • Apovian is professor at Harvard Medical School and co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, Boston, Mass.
  • I felt that the audience had confidence in the results because of the precision with which the study was executed.
  • To view a copy of the study titled "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," visit The New England Journal of Medicine website.
  • Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity.

The Institute for Value-Based Medicine® from The American Journal of Managed Care® Hosts Event to Address Food Insecurity, Obesity and Chronic Conditions in Louisiana

Retrieved on: 
Thursday, November 2, 2023

The Institute for Value-Based Medicine (IVBM) is renowned for promoting value-based care and advancing healthcare practices.

Key Points: 
  • The Institute for Value-Based Medicine (IVBM) is renowned for promoting value-based care and advancing healthcare practices.
  • This upcoming event brings together panels of distinguished healthcare and community experts who will delve into the latest innovations of value-based care.
  • Together, they will discuss ways to address food insecurity, obesity and chronic conditions, which are major challenges in Louisiana.
  • Lacking access to nutritional food can lead to or worsen chronic conditions, or those that require ongoing medical attention.

ARTHEx Biotech Announces Sponsorship and Participation in the Spanish Meeting on Oligonucleotide Therapeutics (SMOT III)

Retrieved on: 
Tuesday, October 24, 2023

SMOT III is supported by the Conselleria D'Innovació, Universitats, Ciencies i Societat Digital of the Generalitat Valenciana, the Oligonucleotide Therapeutics Society (OTS), and its sponsoring companies, including ARTHEx.

Key Points: 
  • SMOT III is supported by the Conselleria D'Innovació, Universitats, Ciencies i Societat Digital of the Generalitat Valenciana, the Oligonucleotide Therapeutics Society (OTS), and its sponsoring companies, including ARTHEx.
  • ARTHEx and the biomedical research center of Hospital La Fe (IIS La Fe), are organizing the event.
  • In addition, ARTHEx's CSO and co-founder, Beatriz Llamusi, is one of the welcome/closing speakers to the event and will be Chairwoman of certain meeting sessions.
  • Details of the ARTHEx presentations during SMOT III are below:
    More information about SMOT III, including registration details and the program, is located here: link .

TOS Recognizes National Childhood Obesity Awareness Month in September Advances in Evidence-Based Treatment, But Barriers to Care Remain

Retrieved on: 
Friday, September 1, 2023

However, significant barriers to care remain, including equitable access and coverage for the care of children and adolescents living with obesity.

Key Points: 
  • However, significant barriers to care remain, including equitable access and coverage for the care of children and adolescents living with obesity.
  • The Obesity Society (TOS) recognizes these challenges noting that more work needs to be done to combat the disease as it marks National Childhood Obesity Awareness Month in September.
  • Huge strides have been made in offering a wide range of effective treatment options to children and adolescents with obesity.
  • Despite this statistic, TOS's pediatric obesity experts remain hopeful that the new AAP guidelines and initiatives such as National Childhood Obesity Awareness Month will help increase awareness and reduce the number of children impacted by obesity.

Wondr Health Introduces Innovative Solution to Navigate the Complexities of Weight-Loss Medications

Retrieved on: 
Thursday, March 23, 2023

Dallas, TX, March 23, 2023 (GLOBE NEWSWIRE) -- Building on the success of its world-class weight-management program Wondr, Wondr Health today announces Wondr Advanced, a comprehensive solution to address the obesity epidemic and drive down health-care costs.

Key Points: 
  • Dallas, TX, March 23, 2023 (GLOBE NEWSWIRE) -- Building on the success of its world-class weight-management program Wondr, Wondr Health today announces Wondr Advanced, a comprehensive solution to address the obesity epidemic and drive down health-care costs.
  • Wondr Advanced brings industry-leading expertise to help organizations navigate the complexities of weight and anti-obesity medications (AOMs) for their population.
  • “Obesity and related health-care costs are on the rise and the demand for anti-obesity medications (AOMs) has surged,” said Tim Church, MD, MPH, PHD, Chief Medical Officer, Wondr Health.
  • “Wondr Health continues to evolve our solutions to meet the needs of our users, employers, and health plan partners,” said Bill Bradford, Chief Commercial Officer, Wondr Health.

Metabolic Health Program Combining GLP-1 Medication with Behavior Change Publishes Annual Results Demonstrating 15% Average Weight Loss at 12, 18, & 24 Months and Reversal of Diabetes or Prediabetes Diagnosis in 81% of Participants

Retrieved on: 
Tuesday, February 21, 2023

Calibrate, the leading metabolic health company, released its second annual Results Report , demonstrating continued effectiveness of the Company’s comprehensive care model to treat overweight and obesity, including a 15% average sustained weight loss at 12, 18, and 24 months.

Key Points: 
  • Calibrate, the leading metabolic health company, released its second annual Results Report , demonstrating continued effectiveness of the Company’s comprehensive care model to treat overweight and obesity, including a 15% average sustained weight loss at 12, 18, and 24 months.
  • The clinically-reviewed data demonstrates overall metabolic health improvements, and notably, the reversal of diabetes and prediabetes diagnoses in 81% of members.
  • “Our most recent Results Report validates our initial vision: that a comprehensive program combining medication with behavior change is the standard of care for obesity treatment.
  • “This is remarkable because it shows more sustained weight loss than the STEP 5 trials using Wegovy––while using a variety of different GLP-1 medications.

AdvoCare® Hosts “You’ve Got This” Virtual Event on February 15th Offering Health and Wellness Education

Retrieved on: 
Monday, February 13, 2023

AdvoCare International, LLC , a health and wellness company, hosts its annual “You’ve Got This” virtual event with a focus on health and wellness in 2023.

Key Points: 
  • AdvoCare International, LLC , a health and wellness company, hosts its annual “You’ve Got This” virtual event with a focus on health and wellness in 2023.
  • This live-streamed event will take place on February 15th from 6:00 pm to 7:30pm (CST) and is offered to registrants at no cost.
  • View the full release here: https://www.businesswire.com/news/home/20230210005320/en/
    Join Jason Witten and Dr. Elizabeth Lombardo for AdvoCare's You've Got This Virtual Event on February 15th from 6pm - 7:30pm.
  • You’ve Got This event registration is free and open to the public.

Obesity-focused Organizations Issue Statement in Support of New AAP Clinical Guideline on Childhood Obesity

Retrieved on: 
Friday, January 13, 2023

On Jan. 9, 2023, AAP published its first clinical practice guideline on the treatment of childhood obesity, replacing recommendations last made in 2007.

Key Points: 
  • On Jan. 9, 2023, AAP published its first clinical practice guideline on the treatment of childhood obesity, replacing recommendations last made in 2007.
  • TOS and OAC support the evidence-based view of obesity presented in the guideline.
  • The Obesity Society's Pediatric Obesity Treatment Task Force emphasizes that pediatric obesity is a disease.
  • The Obesity Action Coalition (OAC) is a national nonprofit organization dedicated to elevating and empowering individuals affected by obesity through education, advocacy and support.

FIU wins $19.4M NIH grant to fight health disparities

Retrieved on: 
Tuesday, November 15, 2022

In 2017, FIU's Community-Based Research Institute won a $13.1 million grant from the National Institutes of Health (NIH) to build the Research Center in a Minority Institution at FIU (FIU-RCMI), which focused on world-class, community-partnered health disparities research and training.

Key Points: 
  • In 2017, FIU's Community-Based Research Institute won a $13.1 million grant from the National Institutes of Health (NIH) to build the Research Center in a Minority Institution at FIU (FIU-RCMI), which focused on world-class, community-partnered health disparities research and training.
  • In recognition of the FIU-RCMI's exceptional performance and its plans for expansion, NIH just renewed the FIU-RCMI with a 5-year, $19.4 million grant, which is the university's largest NIH award to date.
  • "The FIU-RCMI has and will continue to drive FIU's outstanding growth in research capacity in the area of health disparities," said FIU President Kenneth A. Jessell.
  • The new grant will allow the FIU-RCMI to expand its scope to:
    Address HIV and COVID-19 disparities among people with HIV.

WW ANNOUNCES STUDY RESULTS SHOWING CLINICALLY SIGNIFICANT IMPROVEMENTS FOR PEOPLE LIVING WITH DIABETES ON CUSTOMIZED PROGRAM

Retrieved on: 
Saturday, June 4, 2022

NEW YORK, June 4, 2022 /PRNewswire/ -- WW International, Inc. (NASDAQ: WW) ("WeightWatchers," "WW," or "the Company") announced today, at the American Diabetes Association (ADA) 82nd Scientific Sessions, positive results from its three-center clinical trial testing the effectiveness of its program tailored for those living with diabetes on weight management, as well as overall health and well-being.

Key Points: 
  • Results demonstrated that the WeightWatchers diabetes-tailored program had clinically meaningful and statistically significant effects, including:
    Reduction in HbA1c by 0.76.
  • "We remain committed to supporting people living with diabetes with scalable solutions and are encouraged by the positive clinical trial results presented at ADA."
  • The PersonalPoints program can also be further personalized to meet the needs of those living with diabetes.
  • "These trial results show that the WW diabetes-tailored program produces favorable improvements in glycemic control, weight, and diabetes distress which are both statistically significant and clinically meaningful."